TAM (Treatments and Medicines) NHS Highland
Important: Therapy notes
Important: Formulation and dosage details
Formulation:
Modified release tablets (Priadel®) 200mg (5·4mmol lithium/tablet), 400mg (10·8mmol lithium/tablet) (s)
Lithium (Formulary)
Lithium has a narrow therapeutic index and regular physical health monitoring is required. See: CMO(2019)04: National guidance for monitoring Lithium. This includes regular therapeutic drug monitoring. If lithium toxicity develops seek specialist advice. Early features include an exacerbation of existing side-effects: nausea, vomiting and tremor. As toxicity develops further, disorientation and dysarthria appear, followed by convulsions, coma and eventually death from cardiac effects or pulmonary complication.
| Note: Lithium • Always prescribe the same brand of lithium to avoid differences in bioavailablity. • All patients starting lithium should be offered written information; ensure your patient has a copy of the Choice and Medication lithium patient information leaflet. • In long-term use lithium has been associated with thyroid disorders and mild cognitive and memory impairment. • Avoid abrupt cessation of lithium. NICE recommends titrating down over 3 months routinely. |
Important: Therapy notes
Important: Formulation and dosage details
Formulation:
Oral solution (Priadel®) 520mg/5mL (5·5mmol lithium/5mL) (s)